Jazz Pharmaceuticals is set to acquire GW Pharmaceuticals and gain access to a diversified pipeline of cannabis-based medications,…
Joana Carvalho, PhD
Joana holds a bachelor’s in biology, a Master of Science in evolutionary and developmental biology, and a PhD in biomedical sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — those that make up the lining of blood vessels — found in the umbilical cord of newborns. In addition to several research fellowships, she was awarded two Erasmus scholarships to conduct part of her studies in France.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Joana Carvalho, PhD
Diacomit (stiripentol) is safe and effective at reducing the frequency of different types of seizures in people with…
By implementing a free-of-charge epilepsy genetic testing program, it is possible to lower the average age of molecular diagnosis of…
Children with Dravet syndrome receiving Fintepla (fenfluramine) to control their seizures are unlikely to develop…
Used in addition to standard treatments, therapeutic hypothermia — based on lowering the body’s temperature — can shorten the…
Epidiolex, the first plant-derived cannabidiol (CBD) medication to be approved by the U.S. Food and…
In addition to promoting the release of serotonin, a brain chemical typically associated with feelings of well-being and happiness, …
An antisense oligonucleotide therapy that lowers the amount of Scn8a transcripts — RNA molecules used as a template for the…
Fintepla (fenfluramine) reduced the frequency of convulsive seizures in children and adolescents with Dravet syndrome who responded poorly…
Stoke’s STK-001 Prolongs Survival, Reduces Seizures in Dravet Mouse Model, Preclinical Study Shows
STK-001, Stoke Therapeutics’s investigational therapy for Dravet syndrome, prolongs survival and reduces the frequency of seizures in…